Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Neoplasms, Plasma Cell 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 20fludarabine phosphate 16Busulfan 13Antilymphocyte Serum 13Peripheral Blood Stem Cell Transplantation 12Mycophenolic Acid 12Cyclosporine 11Tacrolimus 9Methylprednisolone 8Filgrastim 8Epoetin Alfa 8Cord Blood Stem Cell Transplantation 7Whole-Body Irradiation 6Radiotherapy 6Methotrexate 6Melphalan 5Etoposide 4Darbepoetin alfa 4Cytarabine 4fludarabine 3Therapeutics 2Immunoenzyme Techniques 2Granulocyte Colony-Stimulating Factor 2Carmustine 2tipifarnib 1sargramostim 1ferrous sulfate 1ferric gluconate 1epoetin beta 1entinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Plasma Cell × Glycopeptides × Classical hematology × Clear all
NCT00195533 2009-11-16

Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients

Wyeth is now a wholly owned subsidiary of Pfizer

Completed
801 enrolled
Classical hematologyLymphoidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡